Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The awards cover 55,867 shares and vest over about four years, according to the company.
- On September 3 and 4, 2026, GRAIL, Inc., Spero Therapeutics, Inc., and Apnimed, Inc. announced inducement equity grants for new hires, authorized under Nasdaq Listing Rule 5635.
- Nasdaq Listing Rule 5635 permits companies to grant equity awards to new employees outside standard incentive plans as material inducement for hiring. The plan is used exclusively for individuals not previously employed or after bona fide non-employment periods.
- GRAIL granted restricted stock units underlying 55,867 shares to 59 new employees. Spero Therapeutics approved 102,000 restricted stock units and 67,600 stock options on September 1, 2026.
- Apnimed reported that on August 31, 2026, its compensation committee granted non-qualified stock options for 428,428 shares to 10 new employees at $26.85 per share, matching the September 1, 2026 closing price.
- Equity awards typically vest over multi-year periods, with 25% vesting after one year and the remainder vesting annually thereafter, contingent on continued employment through vesting dates such as August 31, 2027 and September 1, 2027.
11 Articles
11 Articles
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common…
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to…
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock…
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
